Donghua Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donghua Xu has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
Chunjuan Yang
Medical Research Center, Weifang People's Hospital, Shandong Second Medical University, Weifang, 261000, Shandong, China
16 shared publicationsShushan Yan
16 shared publications- Shushan Yan
Department of Gastrointestinal and Anal Diseases Surgery, The Affiliated Hospital of Weifang Medical University, Weifang 261000, China
9 shared publications Wenchang Sun
Medical Research Center, Weifang People's Hospital, Shandong Second Medical University, Weifang, 261000, Shandong, China
9 shared publicationsHui Wang
Medical Research Center, Weifang People's Hospital, Shandong Second Medical University, Weifang, 261000, Shandong, China
8 shared publicationsJinjin Chu
Medical Research Center, Weifang People’s Hospital, Shandong Second Medical University, Weifang, China
8 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Springer Nature in Cell Death & Disease
S100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression
Dysregulated choline metabolism is an established metabolic hallmark that fuels hepatic inflammation and tumorigenesis. However, the upstream regulators of this pathway in hepatocellular carcinoma (HCC) are incompletely understood. Here, we identify S100 calcium-binding protein A16 (S100A16) as a pivotal driver of HCC that operates through choline metabolic reprogramming. Integrated transcriptomic and metabolomic analyses revealed a strong association between S100A16 upregulation and choline metabolism dysregulation in HCC. Clinically, S100A16 was significantly elevated in HCC tissues and patient sera, and its high expression correlated with poor overall and disease-free survival. Functionally, S100A16 overexpression promoted, while its knockdown suppressed HCC cell proliferation, invasion, migration, endoplasmic reticulum (ER) stress, and the production of metabolite phosphatidylcholine in vitro. Consistent with this, S100A16 overexpression potentiated tumor growth in subcutaneous xenograft models and enhanced pulmonary metastasis in vivo. Mechanistically, we delineated a novel signaling axis wherein S100A16 activates the Wnt5A/B-β-catenin pathway, leading to the upregulation of potassium inwardly-rectifying channel subfamily J member 8 (KCNJ8), which in turn drives choline metabolism dysregulation and ER stress. Importantly, hepatocyte-specific conditional knockout of S100A16 in a murine HCC model not only attenuated these oncogenic processes but also remodeled the immunosuppressive tumor microenvironment by rescuing CD8 + T cell exhaustion and reducing the infiltration of CD206 + M2-type tumor-associated macrophages. In summary, our study unveils S100A16 as a central regulator of choline metabolism and immunosuppression in HCC, positioning it as a promising diagnostic biomarker and therapeutic target for this cancer.
- 18 November 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessS100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression
Dysregulated choline metabolism is an established metabolic hallmark that fuels hepatic inflammation and tumorigenesis. However, the upstream regulators of this pathway in hepatocellular carcinoma (HCC) are incompletely understood. Here, we identify S100 calcium-binding protein A16 (S100A16) as a pivotal driver of HCC that operates through choline metabolic reprogramming. Integrated transcriptomic and metabolomic analyses revealed a strong association between S100A16 upregulation and choline metabolism dysregulation in HCC. Clinically, S100A16 was significantly elevated in HCC tissues and patient sera, and its high expression correlated with poor overall and disease-free survival. Functionally, S100A16 overexpression promoted, while its knockdown suppressed HCC cell proliferation, invasion, migration, endoplasmic reticulum (ER) stress, and the production of metabolite phosphatidylcholine in vitro. Consistent with this, S100A16 overexpression potentiated tumor growth in subcutaneous xenograft models and enhanced pulmonary metastasis in vivo. Mechanistically, we delineated a novel signaling axis wherein S100A16 activates the Wnt5A/B-β-catenin pathway, leading to the upregulation of potassium inwardly-rectifying channel subfamily J member 8 (KCNJ8), which in turn drives choline metabolism dysregulation and ER stress. Importantly, hepatocyte-specific conditional knockout of S100A16 in a murine HCC model not only attenuated these oncogenic processes but also remodeled the immunosuppressive tumor microenvironment by rescuing CD8 + T cell exhaustion and reducing the infiltration of CD206 + M2-type tumor-associated macrophages. In summary, our study unveils S100A16 as a central regulator of choline metabolism and immunosuppression in HCC, positioning it as a promising diagnostic biomarker and therapeutic target for this cancer.
- Open Access
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1838554
Mesenchymal stem cells-derived extracellular vesicles as a novel drug delivery carrier: engineering strategies and clinical safety estimation
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have biocompatibility and low immunogenicity. They can effectively mediate intercellular communication by transmitting various information molecules, including polypeptides, lipids, and nucleic acids, thereby demonstrating unique potential in the field of drug delivery. Given their crucial roles in immune regulation and regenerative medicine, an increasing number of studies are focusing on developing MSC-EVs as drug carriers. This paper presents a systematic review of the future development directions of MSC-EVs as drug carriers, with a particular emphasis on their origins and engineering modification or pretreatment strategies. By employing engineering techniques to modify MSC-EVs, it is possible to precisely regulate key properties such as drug-loading capacity and targeting ability, thereby providing a novel approach for efficient drug delivery. Meanwhile, this paper delves into the safety evaluation of MSC-EVs in clinical applications across different diseases, comprehensively assessing their safety and efficacy as drug carriers based on clinical studies in the fields of lungs, skin, nervous system, eyes, and gastrointestinal tract, among others. Furthermore, we provide an outlook on the potential value and challenges associated with the clinical application of MSC-EVs as drug carriers in various diseases in the future, aiming to offer theoretical support and research directions for promoting MSC-EVs as safe and effective drug carriers.
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1838554
Open AccessMesenchymal stem cells-derived extracellular vesicles as a novel drug delivery carrier: engineering strategies and clinical safety estimation
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have biocompatibility and low immunogenicity. They can effectively mediate intercellular communication by transmitting various information molecules, including polypeptides, lipids, and nucleic acids, thereby demonstrating unique potential in the field of drug delivery. Given their crucial roles in immune regulation and regenerative medicine, an increasing number of studies are focusing on developing MSC-EVs as drug carriers. This paper presents a systematic review of the future development directions of MSC-EVs as drug carriers, with a particular emphasis on their origins and engineering modification or pretreatment strategies. By employing engineering techniques to modify MSC-EVs, it is possible to precisely regulate key properties such as drug-loading capacity and targeting ability, thereby providing a novel approach for efficient drug delivery. Meanwhile, this paper delves into the safety evaluation of MSC-EVs in clinical applications across different diseases, comprehensively assessing their safety and efficacy as drug carriers based on clinical studies in the fields of lungs, skin, nervous system, eyes, and gastrointestinal tract, among others. Furthermore, we provide an outlook on the potential value and challenges associated with the clinical application of MSC-EVs as drug carriers in various diseases in the future, aiming to offer theoretical support and research directions for promoting MSC-EVs as safe and effective drug carriers.
- Open Access
- 30 March 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Plasma exosomal fibroblast activation protein: a novel biomarker links fatty acid metabolic dysregulation to systemic lupus erythematosus
Immunometabolic dysregulation is increasingly recognized as a pivotal contributor to systemic lupus erythematosus (SLE). This study aims to identify novel circulating biomarkers within plasma exosomes that link fatty acid metabolic rewiring to SLE pathogenesis. Plasma exosomes were isolated from patients with active SLE, inactive SLE, rheumatoid arthritis (RA) and healthy controls by ultracentrifugation. The proteomic and metabolomic profiles were characterized using liquid chromatography-mass spectrometry (LC-MS). Exosomal fibroblast activation protein (FAP) expression was validated by nanoflow cytometry, and fatty acid metabolites were confirmed by targeted metabolomics. Proteomic profiling revealed a marked enrichment of FAP in plasma exosomes from SLE patients, with the highest levels in active SLE. Nanoflow cytometry further validated that plasma exosomal FAP was specifically increased in SLE but not RA. Besides, metabolomics identified a characteristic fatty acid signature in SLE plasma exosomes, featuring increased saturated (palmitic acid, etc) and ω-6 polyunsaturated fatty acids (PUFAs) (arachidonic acid (AA), etc), alongside decreased ω-3 PUFAs (α-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), etc). Moreover, the AA/DHA and total ω-6/ω-3 ratios were significantly elevated, while the EPA/AA ratio was reduced in active SLE. Integrated omics analysis revealed the close relationship of exosomal FAP with fatty acid metabolism. Notably, exosomal FAP levels correlated positively with SLEDAI-2000 score and the pro-inflammatory fatty acid profiles (AA, total ω-6, AA/DHA ratio), but negatively with the anti-inflammatory profiles (DHA, EPA, total ω-3, EPA/AA ratio). We identify plasma exosomal FAP as a novel biomarker linking fatty acid metabolic dysregulation to SLE. The online version contains supplementary material available at 10.1186/s13075-026-03801-1.
- 30 March 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessPlasma exosomal fibroblast activation protein: a novel biomarker links fatty acid metabolic dysregulation to systemic lupus erythematosus
Immunometabolic dysregulation is increasingly recognized as a pivotal contributor to systemic lupus erythematosus (SLE). This study aims to identify novel circulating biomarkers within plasma exosomes that link fatty acid metabolic rewiring to SLE pathogenesis. Plasma exosomes were isolated from patients with active SLE, inactive SLE, rheumatoid arthritis (RA) and healthy controls by ultracentrifugation. The proteomic and metabolomic profiles were characterized using liquid chromatography-mass spectrometry (LC-MS). Exosomal fibroblast activation protein (FAP) expression was validated by nanoflow cytometry, and fatty acid metabolites were confirmed by targeted metabolomics. Proteomic profiling revealed a marked enrichment of FAP in plasma exosomes from SLE patients, with the highest levels in active SLE. Nanoflow cytometry further validated that plasma exosomal FAP was specifically increased in SLE but not RA. Besides, metabolomics identified a characteristic fatty acid signature in SLE plasma exosomes, featuring increased saturated (palmitic acid, etc) and ω-6 polyunsaturated fatty acids (PUFAs) (arachidonic acid (AA), etc), alongside decreased ω-3 PUFAs (α-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), etc). Moreover, the AA/DHA and total ω-6/ω-3 ratios were significantly elevated, while the EPA/AA ratio was reduced in active SLE. Integrated omics analysis revealed the close relationship of exosomal FAP with fatty acid metabolism. Notably, exosomal FAP levels correlated positively with SLEDAI-2000 score and the pro-inflammatory fatty acid profiles (AA, total ω-6, AA/DHA ratio), but negatively with the anti-inflammatory profiles (DHA, EPA, total ω-3, EPA/AA ratio). We identify plasma exosomal FAP as a novel biomarker linking fatty acid metabolic dysregulation to SLE. The online version contains supplementary material available at 10.1186/s13075-026-03801-1.
- Open Access
- 27 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
MSC-derived exosomes ameliorate systemic lupus erythematosus by reprogramming macrophage mitochondrial homeostasis via the CMPK2-cGAS-STING axis
Mesenchymal stem cell-derived exosomes (MSC-exo), natural functional nanovesicles, are considered a potent alternative for MSC therapy for the treatment of
- 27 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessMSC-derived exosomes ameliorate systemic lupus erythematosus by reprogramming macrophage mitochondrial homeostasis via the CMPK2-cGAS-STING axis
Mesenchymal stem cell-derived exosomes (MSC-exo), natural functional nanovesicles, are considered a potent alternative for MSC therapy for the treatment of
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e1718207
Lnc‐CHRM4‐2:1 Inhibits M2 Polarization and Efferocytosis of Macrophages by Downregulating MerTK and SLC2A1 in Rheumatoid Arthritis
Objective: Rheumatoid arthritis (RA) is a common chronic and systemic autoimmune disease. Long noncoding RNAs (lncRNAs) have been documented to play important roles in the pathogenesis of RA. This study is aimed to investigate the differentially expressed lncRNAs in RA and explore the underlying roles and mechanisms of RA‐specific lncRNAs. Methods: Peripheral blood mononuclear cells (PBMCs) from three RA patients and three healthy controls were detected by transcriptome sequencing analysis. Enrichment analysis was performed to identify the potential functional categories and signal pathways. The expressions of the screened dysregulated lncRNAs in RA were further validated using quantitative real‐time polymerase chain reaction (qRT‐PCR). The effects of the candidate lncRNA lnc‐CHRM4‐2:1 on the proliferation and apoptosis of Raw264.7 cells were determined by cell counting kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU) proliferation assays, and Annexin V‐APC/PI staining flow cytometry assay. qRT‐PCR and western blot were performed to detect the expression of functional molecules related to M1/M2 macrophage polarization and efferocytosis. Results: The expression of lnc‐CHRM4‐2:1 was significantly higher in PBMCs of RA patients compared to healthy controls. Lnc‐CHRM4‐2:1 was negatively associated with the level of serum CCP of RA patients, suggesting that it was a RA‐specific lncRNA. Overexpression of lnc‐CHRM4‐2:1 could potentially affect cell proliferation and apoptosis, promote M1 polarization, inhibit M2 polarization, and the mRNA and protein expressions of MerTK and SLC2A1 in Raw264.7 cells. Conclusion: Lnc‐CHRM4‐2:1 is an RA‐specific lncRNA, which inhibits macrophage M2 polarization and efferocytosis by downregulating MerTK and SLC2A1. Lnc‐CHRM4‐2:1 may be considered a potential diagnostic biomarker and therapeutic target for RA.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e1718207
Open AccessLnc‐CHRM4‐2:1 Inhibits M2 Polarization and Efferocytosis of Macrophages by Downregulating MerTK and SLC2A1 in Rheumatoid Arthritis
Objective: Rheumatoid arthritis (RA) is a common chronic and systemic autoimmune disease. Long noncoding RNAs (lncRNAs) have been documented to play important roles in the pathogenesis of RA. This study is aimed to investigate the differentially expressed lncRNAs in RA and explore the underlying roles and mechanisms of RA‐specific lncRNAs. Methods: Peripheral blood mononuclear cells (PBMCs) from three RA patients and three healthy controls were detected by transcriptome sequencing analysis. Enrichment analysis was performed to identify the potential functional categories and signal pathways. The expressions of the screened dysregulated lncRNAs in RA were further validated using quantitative real‐time polymerase chain reaction (qRT‐PCR). The effects of the candidate lncRNA lnc‐CHRM4‐2:1 on the proliferation and apoptosis of Raw264.7 cells were determined by cell counting kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU) proliferation assays, and Annexin V‐APC/PI staining flow cytometry assay. qRT‐PCR and western blot were performed to detect the expression of functional molecules related to M1/M2 macrophage polarization and efferocytosis. Results: The expression of lnc‐CHRM4‐2:1 was significantly higher in PBMCs of RA patients compared to healthy controls. Lnc‐CHRM4‐2:1 was negatively associated with the level of serum CCP of RA patients, suggesting that it was a RA‐specific lncRNA. Overexpression of lnc‐CHRM4‐2:1 could potentially affect cell proliferation and apoptosis, promote M1 polarization, inhibit M2 polarization, and the mRNA and protein expressions of MerTK and SLC2A1 in Raw264.7 cells. Conclusion: Lnc‐CHRM4‐2:1 is an RA‐specific lncRNA, which inhibits macrophage M2 polarization and efferocytosis by downregulating MerTK and SLC2A1. Lnc‐CHRM4‐2:1 may be considered a potential diagnostic biomarker and therapeutic target for RA.
- Open Access
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1682098
Transcription factor c-Maf: a checkpoint that programs autoimmunity
The transcription factor c-Maf, a member of the Maf family characterized by its basic domain and b-Zip DNA-binding motif, is a pivotal regulator of immune cells development and function. It governs immune cells growth, differentiation, function, and immune responses. This review explores the mechanistic role of c-Maf and its associated signaling networks in modulating autoimmunity and inflammation. We highlight its dual function as an immune checkpoint that suppresses pathological inflammation while promoting protective immunity, underscoring its therapeutic potential in autoimmune diseases.
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1682098
Open AccessTranscription factor c-Maf: a checkpoint that programs autoimmunity
The transcription factor c-Maf, a member of the Maf family characterized by its basic domain and b-Zip DNA-binding motif, is a pivotal regulator of immune cells development and function. It governs immune cells growth, differentiation, function, and immune responses. This review explores the mechanistic role of c-Maf and its associated signaling networks in modulating autoimmunity and inflammation. We highlight its dual function as an immune checkpoint that suppresses pathological inflammation while promoting protective immunity, underscoring its therapeutic potential in autoimmune diseases.
- Open Access
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1682649
Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications
Toll-like receptors (TLRs) belong to the family of pattern recognition receptors (PRRs), playing critical roles in linking innate with adaptive immunity by recognizing pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). TLRs and TLR signaling pathways serve as not only the first line of pulmonary defense against pathogens infection but crucial factors in maintaining pulmonary immune homeostasis. However, aberrant activation of TLR signaling leads to inflammation and immune dysregulations, contributing to various pulmonary diseases, including inflammation, infection, fibrosis, and malignancy. This review summarizes the updated roles of TLRs and TLR signaling in lung development and the establishment and regulation of pulmonary region-specific immunity. We further elucidate the involvement of TLRs and TLR signaling in the onset and progression of lung diseases, such as infections, fibrosis, malignancies, and immune disorders. It would provide updated insights into the exploration of novel diagnostic and therapeutic strategies targeting TLRs and TLR signaling in pulmonary diseases.
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1682649
Open AccessRole of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications
Toll-like receptors (TLRs) belong to the family of pattern recognition receptors (PRRs), playing critical roles in linking innate with adaptive immunity by recognizing pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). TLRs and TLR signaling pathways serve as not only the first line of pulmonary defense against pathogens infection but crucial factors in maintaining pulmonary immune homeostasis. However, aberrant activation of TLR signaling leads to inflammation and immune dysregulations, contributing to various pulmonary diseases, including inflammation, infection, fibrosis, and malignancy. This review summarizes the updated roles of TLRs and TLR signaling in lung development and the establishment and regulation of pulmonary region-specific immunity. We further elucidate the involvement of TLRs and TLR signaling in the onset and progression of lung diseases, such as infections, fibrosis, malignancies, and immune disorders. It would provide updated insights into the exploration of novel diagnostic and therapeutic strategies targeting TLRs and TLR signaling in pulmonary diseases.
- Open Access
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1503140
Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives
Dermatomyositis (DM) is an idiopathic inflammatory myopathy with characteristic cutaneous inflammation and heterogeneous systemic involvements, and is strongly associated with risk of malignancy. This review summarizes the incidence of malignancies, risk factors associated with malignancies, and cancer screening methods in DM patients. Large population-based cohort studies and meta-analyses have provided strong evidence for the significantly elevated incidence of malignancies in DM patients. Common malignancies occurring in DM patients mainly include ovarian cancer, lung cancer, breast cancer, pancreatic cancer, stomach cancer, hematologic malignancies, and colorectal cancer. Clinicians should cautiously consider the risk of malignancy in DM patients during diagnosis and treatment, conducting regular screening and monitoring to facilitate early detection and treatment of malignancies. Among myositis-specific antibodies, anti-transcription intermediary factor 1γ antibodies are strongly linked to malignancy risk. Other factors such as older age, male gender, dysphagia, skin necrosis, cutaneous vasculitis, rapid onset of the disease, elevated creatinine kinase, and elevated C-reactive protein are closely associated with the risk of malignancy. DM patients with these features need receive screening for malignant tumors or close monitoring and follow-up. DM patients, especially those within 3 years of onset, have a high risk of cancer and should receive careful cancer screening according to their risk stratification. Conventional screening tools such as imaging examinations and tumor marker tests are not effective in detecting malignancies among DM patients. Current cancer screening workflows available for DM patients largely mirror those used in the general population but may not fully address DM-specific characteristics, and the best strategy for screening cancer in DM patients is still lacking. To facilitate earlier detection and diagnosis of DM-associated cancer and thereby improve outcomes, more effective cancer detection tools and personalized malignancy screening workflows specifically tailored to the features of DM and their individual risk stratification are warranted.
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1503140
Open AccessRisk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives
Dermatomyositis (DM) is an idiopathic inflammatory myopathy with characteristic cutaneous inflammation and heterogeneous systemic involvements, and is strongly associated with risk of malignancy. This review summarizes the incidence of malignancies, risk factors associated with malignancies, and cancer screening methods in DM patients. Large population-based cohort studies and meta-analyses have provided strong evidence for the significantly elevated incidence of malignancies in DM patients. Common malignancies occurring in DM patients mainly include ovarian cancer, lung cancer, breast cancer, pancreatic cancer, stomach cancer, hematologic malignancies, and colorectal cancer. Clinicians should cautiously consider the risk of malignancy in DM patients during diagnosis and treatment, conducting regular screening and monitoring to facilitate early detection and treatment of malignancies. Among myositis-specific antibodies, anti-transcription intermediary factor 1γ antibodies are strongly linked to malignancy risk. Other factors such as older age, male gender, dysphagia, skin necrosis, cutaneous vasculitis, rapid onset of the disease, elevated creatinine kinase, and elevated C-reactive protein are closely associated with the risk of malignancy. DM patients with these features need receive screening for malignant tumors or close monitoring and follow-up. DM patients, especially those within 3 years of onset, have a high risk of cancer and should receive careful cancer screening according to their risk stratification. Conventional screening tools such as imaging examinations and tumor marker tests are not effective in detecting malignancies among DM patients. Current cancer screening workflows available for DM patients largely mirror those used in the general population but may not fully address DM-specific characteristics, and the best strategy for screening cancer in DM patients is still lacking. To facilitate earlier detection and diagnosis of DM-associated cancer and thereby improve outcomes, more effective cancer detection tools and personalized malignancy screening workflows specifically tailored to the features of DM and their individual risk stratification are warranted.
- Open Access
- 3 June 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (6) , e0157624
Unraveling the interplay between mesenchymal stem cells, gut microbiota, and systemic sclerosis: therapeutic implications
Systemic sclerosis (SSc) is an autoimmune disease with progressive fibrotic disorders in multiple organs. Mesenchymal stem cells (MSCs) have shown great potential in treating SSc, but the exact regulatory mechanism is not fully understood. In this study, we used human umbilical cord-derived MSCs (hUC-MSCs) to treat SSc mice induced by bleomycin. The gut microbiota composition and predicted functions were analyzed using 2bRAD sequencing of fecal samples from control, SSc, and MSCs-treated mice. Treatment with MSCs improved the bleomycin-induced SSc mice, characterized by significantly reduced collagen deposition and dermal thickness. The gut microbiota of SSc mice exhibited lower species evenness and was clearly separated from the control mice based on beta diversity. MSC treatment led to a significant reduction of conditionally pathogenic bacteria enriched in SSc, including Akkermansia muciniphila and Parasutterella excrementihominis . Conversely, the relative abundance of butyrate-producing bacteria, such as Roseburia , Butyricicoccus porcorum , and Gemmiger formicilis , was notably increased in MSCs-treated SSc mice. Additionally, the functional analysis revealed that MSCs intervention effectively enhanced sulfur metabolism, tryptophan metabolism, citrate cycle, RNA polymerase, and beta-lactam resistance. In summary, the findings in the present study have suggested the close association between gut microbiota and metabolic dysbiosis in mice with SSc. The administration of MSCs has been shown to regulate the disrupted metabolic pathways in SSc mice, thus restoring the normal function of the gut microbiota. This study provides valuable insights into the specific gut microbiota and metabolic pathways involved in the efficacy of MSC treatment, thereby proposing a novel therapeutic strategy for SSc. IMPORTANCE: Human umbilical cord-derived mesenchymal stem cells (HUC‑MSCs) demonstrate efficacy in alleviating skin thickening and collagen deposition in systemic sclerosis (SSc) mice, which also regulate the gut microbiota composition and function. Specifically, MSC intervention leads to a notable increase in butyrate-producing bacteria, a decrease in Akkermansia muciniphila and Parasutterella excrementihominis , and a reversal of the dysregulated microbial function in SSc mice. These findings underscore the potential significance of gut microbiota in the therapeutic effects of MSCs in SSc.
- 3 June 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (6) , e0157624
Open AccessUnraveling the interplay between mesenchymal stem cells, gut microbiota, and systemic sclerosis: therapeutic implications
Systemic sclerosis (SSc) is an autoimmune disease with progressive fibrotic disorders in multiple organs. Mesenchymal stem cells (MSCs) have shown great potential in treating SSc, but the exact regulatory mechanism is not fully understood. In this study, we used human umbilical cord-derived MSCs (hUC-MSCs) to treat SSc mice induced by bleomycin. The gut microbiota composition and predicted functions were analyzed using 2bRAD sequencing of fecal samples from control, SSc, and MSCs-treated mice. Treatment with MSCs improved the bleomycin-induced SSc mice, characterized by significantly reduced collagen deposition and dermal thickness. The gut microbiota of SSc mice exhibited lower species evenness and was clearly separated from the control mice based on beta diversity. MSC treatment led to a significant reduction of conditionally pathogenic bacteria enriched in SSc, including Akkermansia muciniphila and Parasutterella excrementihominis . Conversely, the relative abundance of butyrate-producing bacteria, such as Roseburia , Butyricicoccus porcorum , and Gemmiger formicilis , was notably increased in MSCs-treated SSc mice. Additionally, the functional analysis revealed that MSCs intervention effectively enhanced sulfur metabolism, tryptophan metabolism, citrate cycle, RNA polymerase, and beta-lactam resistance. In summary, the findings in the present study have suggested the close association between gut microbiota and metabolic dysbiosis in mice with SSc. The administration of MSCs has been shown to regulate the disrupted metabolic pathways in SSc mice, thus restoring the normal function of the gut microbiota. This study provides valuable insights into the specific gut microbiota and metabolic pathways involved in the efficacy of MSC treatment, thereby proposing a novel therapeutic strategy for SSc. IMPORTANCE: Human umbilical cord-derived mesenchymal stem cells (HUC‑MSCs) demonstrate efficacy in alleviating skin thickening and collagen deposition in systemic sclerosis (SSc) mice, which also regulate the gut microbiota composition and function. Specifically, MSC intervention leads to a notable increase in butyrate-producing bacteria, a decrease in Akkermansia muciniphila and Parasutterella excrementihominis , and a reversal of the dysregulated microbial function in SSc mice. These findings underscore the potential significance of gut microbiota in the therapeutic effects of MSCs in SSc.
- Open Access
- 31 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1548053
Tissue-resident macrophages and renal diseases: landscapes and treatment directions
Tissue-resident macrophage (TRM) is a specialized subset of macrophage that resides within specific tissues and organs. TRMs play crucial roles in resisting pathogen invasion, maintaining the homeostasis of the immune microenvironment, and promoting tissue repair and regeneration. The development and function of TRMs exhibit significant heterogeneity across different tissues. Kidney TRMs (KTRMs) originate from both embryonic yolk sac erythro-myeloid progenitors and the fetal liver, demonstrating the capacity for self-renewal independent of bone marrow hematopoiesis. KTRMs are not only essential for the maintenance of renal homeostasis and the monitoring of microvascular environment, but contribute to renal injury due to inflammation, fibrosis and immune dysfunction in kidneys. In this review, we summarize currently available studies on the regulatory role of KTRMs in processes of renal injury and repair. The altering effects and underlying mechanisms of KTRMs in regulating local tissue cells and immune cells in different renal diseases are reviewed, primarily including lupus nephritis, diabetic nephropathy, renal fibrosis, and renal carcinoma. Understanding the plasticity and immune regulatory functions of KTRMs may offer new insights into the pathogenesis and the exploration of therapeutic strategies of kidney diseases.
- 31 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1548053
Open AccessTissue-resident macrophages and renal diseases: landscapes and treatment directions
Tissue-resident macrophage (TRM) is a specialized subset of macrophage that resides within specific tissues and organs. TRMs play crucial roles in resisting pathogen invasion, maintaining the homeostasis of the immune microenvironment, and promoting tissue repair and regeneration. The development and function of TRMs exhibit significant heterogeneity across different tissues. Kidney TRMs (KTRMs) originate from both embryonic yolk sac erythro-myeloid progenitors and the fetal liver, demonstrating the capacity for self-renewal independent of bone marrow hematopoiesis. KTRMs are not only essential for the maintenance of renal homeostasis and the monitoring of microvascular environment, but contribute to renal injury due to inflammation, fibrosis and immune dysfunction in kidneys. In this review, we summarize currently available studies on the regulatory role of KTRMs in processes of renal injury and repair. The altering effects and underlying mechanisms of KTRMs in regulating local tissue cells and immune cells in different renal diseases are reviewed, primarily including lupus nephritis, diabetic nephropathy, renal fibrosis, and renal carcinoma. Understanding the plasticity and immune regulatory functions of KTRMs may offer new insights into the pathogenesis and the exploration of therapeutic strategies of kidney diseases.